Companies / United Kingdom
AstraZeneca Acquires MedImmune
April 2007 | Company Finance AlertUK-based drugmaker AstraZeneca will enter the vaccines market in strength after agreeing a US$15.2bn fee for US-based biotech MedImmune . The deal, which will significantly boost AstraZeneca's pipeline, comes after the company decided to end development for heart disease treatment AGI-1067, its fourth major failure in the space of a year.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.




